Sofía Aljaro
A5049557203- COVID-19 Clinical Research Studies
- Vaccine Coverage and Hesitancy
- SARS-CoV-2 and COVID-19 Research
- Health and Medical Education
- Public Health and Environmental Issues
Pontificia Universidad Católica de Chile
2022
BackgroundThe Omicron variant has challenged the control of COVID-19 pandemic due to its immuno-evasive properties. The administration a booster dose SARS-CoV-2 vaccine showed positive effects in immunogenicity against SARS-CoV-2, effect that is even enhanced after second booster.MethodsDuring phase-3 clinical trial, we evaluated CoronaVac®, an inactivated administered 6 months first booster, neutralization (n = 87). In parallel, cellular immunity 45) was analyzed stimulated peripheral...
Several vaccines have been developed to control the COVID-19 pandemic. CoronaVac®, an inactivated SARS-CoV-2 vaccine, has demonstrated safety and immunogenicity, preventing severe cases. We investigate non-inferiority of two immunization schedules CoronaVac® in a trial healthy adults. A total 2302 adults were enrolled at 8 centers Chile randomly assigned vaccination schedules, receiving doses with either 14 or 28 days between each. The primary efficacy endpoints solicited adverse events...
Abstract Background Several vaccines have been developed to control the COVID-19 pandemic. CoronaVac ® (Sinovac Life Sciences), an inactivated SARS-CoV-2 vaccine, has demonstrated safety and immunogenicity in previous studies, preventing severe cases. We further investigated efficacy of two immunization schedules a non-inferiority trial healthy adults. Methods This is multi-center randomized clinical trial. Healthy adults were enrolled at eight centers Chile. Participants randomly assigned...
Introducción: La introducción progresiva de vacunas contra SARS-CoV-2 a partir 2021, priorizando grupos mayor edad, podrÃa implicar un cambio en el perfil pacientes hospitalizados por COVID-19 tiempo.